SCHEMBL23218461

SCHEMBL23218461

CCOC(=O)Cc1ccc(OC)cc1OCc1coc2c(NCC3CC3)cc(-c3cccc(CN)c3)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 4/20 0.38
MTNR1A P48039 2/20 0.38
MTNR1B P49286 2/20 0.38
PLG P00747 2/20 0.34
PLAU P00749 2/20 0.34
F11 P03951 2/20 0.34
KLKB1 P03952 2/20 0.34
F7 P08709 1/20 0.34
TPSB2 P20231 1/20 0.34
PTGER4 P35408 2/20 0.34
VDR P11473 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ESR1 P03372 1/20 0.33
THRA P10827 1/20 0.33
THRB P10828 1/20 0.33
RXRA P19793 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852939 1.00 CFD (0.38) CFDMTNR1AMTNR1BPLGPLAU
SCHEMBL23219097 0.97 CFD (0.37) CFDMTNR1AMTNR1BPLGPLAU
SCHEMBL29852798 0.97 CFD (0.37) CFDMTNR1AMTNR1BPLGPLAU
SCHEMBL29852674 0.92 CFD (0.43) CFDMTNR1AMTNR1BPLGPLAU
SCHEMBL23218434 0.92 CFD (0.43) CFDMTNR1AMTNR1BPLGPLAU
SCHEMBL23218705 0.91 CFD (0.46) CFDPLGPLAUF11KLKB1
SCHEMBL29852930 0.91 CFD (0.46) CFDPLGPLAUF11KLKB1
SCHEMBL23218472 0.90 MTNR1A (0.41) CFDMTNR1AMTNR1BPLGPLAU
SCHEMBL29852432 0.90 MTNR1A (0.41) CFDMTNR1AMTNR1BPLGPLAU
SCHEMBL23218154 0.89 MTNR1A (0.38) CFDMTNR1AMTNR1BPLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885MTNR1A 3930/4885MTNR1B 3580/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885MTNR1A 3848/4885MTNR1B 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.